FDA Adjusts Review Timeline to Keep Up with Orphan Drug Demand
The agency says the increasing requests for orphan drug designation has resulted in a change in FDA’s review goals.
In a July 18, 2016 FDAVoice blog post, Gayatri Rao, MD, director of FDA’s Office of Orphan Products Development (OOPD), stated the agency will be revising its goals in regards to the review of orphan drug applications in order for FDA to meet growing demand from the industry for orphan drug designation. FDA’s new timeline goal will be to review appropriate orphan drug applications on an average of 75% of requests within 120 days of receipt.
According to Rao, there was a 30% increase in orphan drug designation applications in 2014, compared to 2013. The interest continued to increase in 2015 when the agency received 470 requests. Rao says that based on requests received so far in 2016, this year could see another 30% increase. Due to the continued increase in requests, the agency may have to reevaluate its review times again in the future.
“We strive to review these requests in an efficient and timely manner because we understand how critical designation can be for companies to move forward with their drug development plans. At the same time, we endeavor to safeguard the intent of the Orphan Drug Act by conducting a thorough review to ensure that the drugs we designate fully satisfy the criteria for designation and the financial incentives associated with designation," Rao says in the blog post.
Rao stresses that companies can help FDA stick to the review timeline by reducing the number of review cycles needed and providing all the necessary information for OOPD to complete its review. FDA recommends companies review information on www.fda.gov/orphan when developing their application.
Orphan drugs are treatments developed to treat rare diseases. The Orphan Drug Act was passed in 1983 and included incentives for companies to develop drugs for rare diseases, including tax credits and market exclusivity.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
